Background: Metformin is the first line treatment for type 2 diabetes mellitus. Sodium glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of oral antidiabetic agents. We aimed to understand factors associated with attaining the HbA1c threshold of <8% in the United States.

Methods: Observational, retrospective cohort study in adult type 2 diabetes mellitus patients from IQVIA EMR database. Observation period was June 2015 to June 2018. Patients needed to initiate SGLT2i and metformin without other antihyperglycemic agents. The impact of sociodemographic factors on achievement of HbA1c <8% was tested using multivariable logistic regression with backward stepwise selection using SAS 9.4.

Results: Of 3491 patients in the final cohort, 2176 (62.3%) achieved HbA1c <8%. The remaining patients had a median distance to goal of 1.1% (IQR 0.5-2.3%). Mean age was 56.5 year. 52.6% were male. Black patients had lower odds to attain HbA1c <8% than white patients [OR 0.69 (0.57, 0.85)], while patients <65 years of age had non relevant higher odds [OR 1.01 (1.01, 1.02)], Table 1.

Conclusion: In the real world in the U.S., 62% of patients treated with metformin and an SGLT2i had an HbA1c <8%. Black patients had lower odds to attain this threshold.


D. Lautsch: Employee; Self; Merck & Co., Inc. L. Yang: Employee; Self; Merck & Co., Inc. S. Rajpathak: Employee; Self; Menarini Group. N. Bansal: None. N. Kathe: None.


Merck & Co., Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at